Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection.
about
Investigational drugs to treat methicillin-resistant Staphylococcus aureusWill there ever be a universal Staphylococcus aureus vaccine?Neutrophil crawling in capillaries; a novel immune response to Staphylococcus aureusPanton-Valentine leukocidin is not the primary determinant of outcome for Staphylococcus aureus skin infections: evaluation from the CANVAS studiesIdentification of a crucial residue required for Staphylococcus aureus LukAB cytotoxicity and receptor recognition.The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections.Seasonal H3N2 influenza A virus fails to enhance Staphylococcus aureus co-infection in a non-human primate respiratory tract infection modelBacterial survival amidst an immune onslaught: the contribution of the Staphylococcus aureus leukotoxins.The bicomponent pore-forming leucocidins of Staphylococcus aureusProduction of an attenuated phenol-soluble modulin variant unique to the MRSA clonal complex 30 increases severity of bloodstream infection.Why antibodies disobey the Hippocratic Oath and end up doing harm: a new clue.Cross-talk between Staphylococcus aureus leukocidins-intoxicated macrophages and lung epithelial cells triggers chemokine secretion in an inflammasome-dependent manner.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infectionApplying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.Characterization of SSR42, a novel virulence factor regulatory RNA that contributes to the pathogenesis of a Staphylococcus aureus USA300 representative.Community-associated MRSA: what makes them special?Designed reduction of Streptococcus pneumoniae pathogenicity via synthetic changes in virulence factor codon-pair biasPanton-Valentine leukocidin antibodies for the treatment of MRSA skin infections?Insights into the Staphylococcus aureus-host interface: global changes in host and pathogen gene expression in a rabbit skin infection model.Frequency of panton-valentine leukocidin-producing methicillin-sensitive Staphylococcus strains in patients with complicated skin and soft tissue infection in bronx, new york.Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection.Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxinsColonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?Characterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesis.Counter inhibition between leukotoxins attenuates Staphylococcus aureus virulence.Sublytic concentrations of Staphylococcus aureus Panton-Valentine leukocidin alter human PMN gene expression and enhance bactericidal capacity.Immune-activating properties of Panton-Valentine leukocidin improve the outcome in a model of methicillin-resistant Staphylococcus aureus pneumonia.Staphylococcus aureus leukotoxin GH promotes inflammation.Staphylococcus aureus elaborates leukocidin AB to mediate escape from within human neutrophilsThe effects of Staphylococcus aureus leukotoxins on the host: cell lysis and beyond.Staphylococcus aureus corneal infections: effect of the Panton-Valentine leukocidin (PVL) and antibody to PVL on virulence and pathology.Staphylococcus aureus leukotoxin GH promotes formation of neutrophil extracellular traps.Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy.Targeting the host-pathogen interface for treatment of Staphylococcus aureus infection.Community-associated methicillin-resistant Staphylococcus aureus and athletes.Pathogenesis of Staphylococcus aureus necrotizing pneumonia: the role of PVL and an influenza coinfection.Staphylococcal bicomponent pore-forming toxins: targets for prophylaxis and immunotherapy.Leukocidins: staphylococcal bi-component pore-forming toxins find their receptors.Lethal CD4 T Cell Responses Induced by Vaccination Against Staphylococcus aureus Bacteremia.
P2860
Q26780246-83305C9B-C662-4925-8C27-981F6834E94AQ26824837-A146BBC2-96CC-4F01-A016-B59BE574AD7BQ27324045-4E762345-6BDD-4548-B07C-7AC974B025CCQ28729864-04F5D80E-9A6A-43B3-9CE1-28102FBDBD3EQ30153456-5A19B1DE-0681-4CDA-BF64-C80F4FF1089AQ30415990-CB479564-32F3-422E-B753-1C257B51661DQ30571941-2E80608B-329A-4DFF-89E6-C391AFBFBE72Q31111609-A239F288-87C7-4D5E-B864-75279037CF26Q33743499-012B36F1-2519-4D42-B0D0-5927136C7992Q34075795-03A1244F-60A6-40D1-B08C-6DDD99B03FAAQ34090255-237DCC47-654D-4CDE-9654-3D21E43CBD9AQ34157497-3F9AA200-61E6-481B-B116-799BE1079C15Q34157657-82CB40D4-8F3B-4735-A86E-7314B085808BQ34233286-9E1EB3A9-317B-4CFB-A9A1-F50765FFEA79Q34250054-60D7573C-5B14-4ABD-B7AA-0E84B998F1B6Q34267292-C87DEA83-38DB-4B13-9290-2D1F346AF932Q34334532-ED28E470-FFEB-46AF-8156-50734EA5EA2DQ34754860-FE384D81-9E90-4109-9B1D-BE7418EDD293Q35020067-59A89F17-2FFD-4AB7-8A0D-1D5B3CE481F4Q35125561-AB800704-0C8E-4117-B519-C39EE6AA166FQ35139743-522B6B0C-993F-4679-88E2-86AEF60E9629Q35167140-DD99B59F-CFB3-4B3F-B8C0-A5FC74F90FDFQ35239977-0EEDDCA1-A7AA-44B0-8CD3-FCC6CC719194Q35736907-211E7C2F-71D5-4F76-9E1D-F5C1680A8908Q35851869-160FA686-2F67-400D-ABE8-8AA39BB09B31Q36035535-B6AED57B-8FFF-416F-8A44-C24CCBADE64CQ36091286-15810171-FBC9-48BB-8BCC-0A3F7048685EQ36211152-8CAD8E3E-2887-4E64-958E-9B7849A198DAQ36253043-90786D9D-32BE-4EA2-9FD5-05B4FC9C5364Q36826997-6F42203D-2BD3-45E4-A50E-04264A8B8F51Q36896790-087A09E2-C16D-44CB-A7A5-9DCA97DD8780Q36979233-E40782A1-DDDA-47CD-993D-D727FAE20ADDQ37520251-02E2219D-A7E2-497C-ABBB-5BC146B2830FQ37819539-913D9C3E-0660-47A0-8CFD-8E7773619400Q37957015-2076DF58-E8B6-4661-BAE8-96F6E6F430FBQ38023627-B153E670-A3F0-4C67-9DB3-5C94B0B6EEA7Q38145284-0ABA4B3C-6981-43A6-B565-E9D5F64608A5Q38193690-14AB3E5E-1FC0-4752-AD61-957AA5251193Q38728618-88C45E19-ED0E-4550-A3F4-DE2ACCDB3D21Q38741540-9F013769-0A4B-4E3F-9986-8C8BAFCE2398
P2860
Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Antibody-mediated enhancement ...... aphylococcus aureus infection.
@ast
Antibody-mediated enhancement ...... aphylococcus aureus infection.
@en
type
label
Antibody-mediated enhancement ...... aphylococcus aureus infection.
@ast
Antibody-mediated enhancement ...... aphylococcus aureus infection.
@en
prefLabel
Antibody-mediated enhancement ...... aphylococcus aureus infection.
@ast
Antibody-mediated enhancement ...... aphylococcus aureus infection.
@en
P2860
P356
P1476
Antibody-mediated enhancement ...... taphylococcus aureus infection
@en
P2093
Pauline Yoong
P2860
P304
P356
10.1073/PNAS.0910344107
P407
P50
P577
2010-01-19T00:00:00Z